Driving Interoperability and Ubiquitous Access to Healthcare Information with Dr. John Blair MedAllies TRANSCRIPT
Release Date: 06/17/2024
Developing Recurring Revenue Health and Wellness Products and Services to Optimize Patient Experience and Build Loyalty with Matt Cronin House of Kaizen TRANSCRIPT
Empowered Patient Podcast
Matt Cronin, Founding Partner of House of Kaizen, discusses how patients' changing healthcare expectations are shaped by their experiences with products and services such as Netflix and Amazon Prime. Consumers now expect a longer-term relationship and personalized experiences with their healthcare providers. House of Kaizen emphasizes the importance of building better customer experiences in health and wellness to improve health outcomes and create more value for businesses. In the age of AI, the importance of trust and brand reputation is paramount. Healthcare providers, as the trusted...
info_outline
Developing Recurring Revenue Health and Wellness Products and Services to Optimize Patient Experience and Build Loyalty with Matt Cronin House of Kaizen
Empowered Patient Podcast
Matt Cronin, Founding Partner of House of Kaizen, discusses how patients' changing healthcare expectations are shaped by their experiences with products and services such as Netflix and Amazon Prime. Consumers now expect a longer-term relationship and personalized experiences with their healthcare providers. House of Kaizen emphasizes the importance of building better customer experiences in health and wellness to improve health outcomes and create more value for businesses. In the age of AI, the importance of trust and brand reputation is paramount. Healthcare providers, as the trusted...
info_outline
Menin Inhibition Shows Potential for Precision Therapy in AML with Dr. Mollie Leoni Kura Oncology TRANSCRIPT
Empowered Patient Podcast
Dr. Mollie Leoni, Executive Vice President for Clinical Development of Kura Oncology, discusses the company's ziftomenib program, a menin inhibitor for acute myeloid leukemia (AML). The company initially allowed all AML patients to participate in the clinical study, but later found that specific subtypes, such as those with NPM1 mutation or KMT2A rearrangement, were more likely to respond to the menin inhibitor. They also discovered other subtypes that were responsive, expanding the potential patient population. Understanding the role of menin and menin inhibitors in addressing abnormal gene...
info_outline
Menin Inhibition Shows Potential for Precision Therapy in AML with Dr. Mollie Leoni Kura Oncology
Empowered Patient Podcast
Dr. Mollie Leoni, Executive Vice President for Clinical Development of Kura Oncology, discusses the company's ziftomenib program, a menin inhibitor for acute myeloid leukemia (AML). The company initially allowed all AML patients to participate in the clinical study, but later found that specific subtypes, such as those with NPM1 mutation or KMT2A rearrangement, were more likely to respond to the menin inhibitor. They also discovered other subtypes that were responsive, expanding the potential patient population. Understanding the role of menin and menin inhibitors in addressing abnormal gene...
info_outline
New Landscape for Controlling Obesity and Lowering Incidence of Related Diseases with Dr. Steffen-Sebastian Bolz Aphaia Pharma TRANSCRIPT
Empowered Patient Podcast
Dr. Steffen-Sebastian Bolz, Chief Scientific Officer of Swiss-based Aphaia Pharma, shines a light on the excitement around weight loss drugs due to the discovery that GLP-1 agonists and points out the shift in the perception of obesity as a root cause of various health issues. Aphaia Pharma's approach involves stimulating hormone production in the small intestine by reinvigorating the mechanism that has become dormant due to the ingestion of highly refined foods. The company is also exploring the effects of the circadian rhythm on weight loss and maintaining a healthy weight. Steffen...
info_outline
New Landscape for Controlling Obesity and Lowering Incidence of Related Diseases with Dr. Steffen-Sebastian Bolz Aphaia Pharma
Empowered Patient Podcast
Dr. Steffen-Sebastian Bolz, Chief Scientific Officer of Swiss-based Aphaia Pharma, shines a light on the excitement around weight loss drugs due to the discovery that GLP-1 agonists and points out the shift in the perception of obesity as a root cause of various health issues. Aphaia Pharma's approach involves stimulating hormone production in the small intestine by reinvigorating the mechanism that has become dormant due to the ingestion of highly refined foods. The company is also exploring the effects of the circadian rhythm on weight loss and maintaining a healthy weight. Steffen...
info_outline
Healthcare Outcomes When Hospitals Embrace Vertical Farming with Rick Vanzura Freight Farms and Dr. Amber Orman Advent Health TRANSCRIPT
Empowered Patient Podcast
Rick Vanzura, CEO of Freight Farms, and Dr. Amber Orman, Chief Wellness Officer at Advent Health, discuss their partnership in bringing hyperlocal, sustainable food to healthcare facilities. Freight Farms uses modified shipping containers to grow crops, allowing for year-round production with minimal land and water usage. Advent Health recognized the importance of nutrition in whole-person care and saw the opportunity to provide their team members, physicians, patients, and the public with fresh, nutritious food and donate to local food pantries. The partnership has demonstrated the power of...
info_outline
Healthcare Outcomes When Hospitals Embrace Vertical Farming with Rick Vanzura Freight Farms and Dr. Amber Orman Advent Health
Empowered Patient Podcast
Rick Vanzura, CEO of Freight Farms, and Dr. Amber Orman, Chief Wellness Officer at Advent Health, discuss their partnership in bringing hyperlocal, sustainable food to healthcare facilities. Freight Farms uses modified shipping containers to grow crops, allowing for year-round production with minimal land and water usage. Advent Health recognized the importance of nutrition in whole-person care and saw the opportunity to provide their team members, physicians, patients, and the public with fresh, nutritious food and donate to local food pantries. The partnership has demonstrated the power of...
info_outline
Advancements in Gene Therapy for Rare Ocular Disease and Metabolic Disorders with Guang Qu NGGT Corporation TRANSCRIPT
Empowered Patient Podcast
Guang Qu, Co-Founder of NGGT Corporation is focused on developing gene therapy products using dual functional vector strategies. Guang highlights the importance of distinguishing between recessive and dominant mutations in rare diseases and explains how their approach differs from other gene therapy approaches. The two leading indications caused by a gene mutation that NGGT is working on are Bietti's Crystalline Dystrophy (BCD), a rare ocular disease, and phenylketonuria (PKU), a metabolic disease. Guang explains, "For our strategies and our product development strategies, I think...
info_outline
Advancements in Gene Therapy for Rare Ocular Disease and Metabolic Disorders with Guang Qu NGGT Corporation
Empowered Patient Podcast
Guang Qu, Co-Founder of NGGT Corporation is focused on developing gene therapy products using dual functional vector strategies. Guang highlights the importance of distinguishing between recessive and dominant mutations in rare diseases and explains how their approach differs from other gene therapy approaches. The two leading indications caused by a gene mutation that NGGT is working on are Bietti's Crystalline Dystrophy (BCD), a rare ocular disease, and phenylketonuria (PKU), a metabolic disease. Guang explains, "For our strategies and our product development strategies, I think...
info_outlineDr. John Blair, CEO of MedAllies, was created to address the lack of communication and coordination between healthcare providers and the importance of interoperability in healthcare. While healthcare has become more complicated over the years, with advancements in technology and automation, the lack of reimbursement for coordination of care has contributed to the problem of lack of interoperability. There are incentives and penalties associated with interoperability, including information blocking and the Trust Exchange Framework and Common Agreement (TEFCA) initiative, which aims to standardize interoperability platforms and reduce barriers to entry for healthcare organizations.
John explains, "But if you look at hospitals, you've got about 70% of the hospitals in the country connected to a national network. That means there's 30% that are not. And then, if you start to break that down and look at rural areas versus urban, there's a big disconnect. These smaller rural hospitals tend to be far less connected than the larger urban hospitals. Then, if you even break it down in the urban areas, you look at certain areas, the more marginalized communities, and again, those hospitals are less likely to be connected. So that's the real issue right now as we're trying to move with interoperability, and as we're making more and more success or having more and more success, there are still those who are falling behind."
"Well, interoperability should improve care and care for an individual, the experience for the individual, the efficiency of the individual getting their care amongst multiple providers, and also improve the efficiency for providers in terms of coordination between other providers. And it will cost money to do that. I mean, it costs money for those connections to run these platforms -- millions and millions of dollars to run these annually."
#MedAllies #HealthcareNetworks #Hospitals #Interoperability #HealthcareCosts #TEFCA
